{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-105344","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.259734+00:00","generated_at":"2026-05-31T05:25:46.839685+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kintara sets Sept 20 vote on TuHURA merger; REM-001 enrolled 4 of 10 patients; warns of bankruptcy without deal","bullets":["Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.","REM-001 CMBC study: 4 of 10 target patients enrolled as of Sept 10, 2024; no safety issues; Phase 3 dose assessment ongoing.","Without the merger, Kintara states it likely lacks adequate resources to continue operations and may seek bankruptcy protection.","Majority of REM-001 costs covered by $2.0M SBIR grant from NIH; potential to offer much needed treatment for CMBC.","CVRs allow additional shares if ≥10 patients enrolled and complete 8-week follow-up by Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-105344","json":"https://secwatch.observer/filing/0000950170-24-105344.json","markdown":"https://secwatch.observer/filing/0000950170-24-105344.md","text":"https://secwatch.observer/filing/0000950170-24-105344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024105344/0000950170-24-105344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024105344/ktra-20240911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:25:46.839685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}